Do you suffer from Depression, Anxiety or Insomnia? Now there’s hope.
•Approximately 14 million people in the U.S. live with this serious illness
•About 4 million of these do not benefit from standard antidepressant medication
An effective, non-drug treatment for Depression, Anxiety and Insomnia that is bringing new hope to patients every day. This is not an experimental treatment. It has been approved by the FDA as a safe and effective for treatment of patients with depression and anxiety who have not benefited from prior antidepressant medication. Cranial Electrotherapy works by stimulating areas of the brain which are underactive in patients with severe depression and anxiety. Because it is not a drug, CES therapy is free from the side effects that patients often experience when they take antidepressant medication.
What happens during the treatment?
Our certified practitioners apply electrodes to the patient’s ear lobes which then connects to a patented microcurrent machine. The treatment is cost effective, non painful and lasts about 20 minutes as the patient lies in a relaxing environment. Unlike drugs, the CES treatments leaves the mind alert with improvements experienced within a few treatments. In fact the reduction of Anxiety is often experienced after only one treatment. Depression and Insomnia are improved after one to two weeks of regular treatments. CES can also help treat the underlying mood disorders associated with pain. It is recommended that patients receive 5-10 treatments in the course of three weeks for maximum results.
How does Cranial Electrotherapy Stimulation (CES) work
Based on previous and ongoing studies, micro current waves activate specific groups of nerve cells that are located at the brainstem. These groups of nerve cells produce the chemicals serotonin and acetylcholine, which can affect the chemical activity of nerve cells in the nervous system. By changing the electrical and chemical activity of certain nerve cells in the brainstem, the current amplifies activity in some neurological systems, and diminishes activity in others. This neurological fine tuning is called modulation, and occurs either as a result of, or together with the production of electrical activity patterns in the brain known as an alpha state. Such alpha rhythms are accompanied by feelings of calmness, relaxation and increased mental focus.
CES has been shown in multiple peer reviewed studies, that it is more efficacious beyond a placebo effect than some of the leading depression treatment medication on the market. It provides significant relief to 9 out of 10 patients that try it.
RECENT STUDY USING THE CES TO TREAT BIPOLAR II DISORDER
Below is a recent double-blind randomized placebo controlled study of cranial electrotherapy stimulation for the treatment of depression in bipolar II disorder at Mt. Sinai.
S Greenman BA, D McClure BA, G Kazariants PhD, M Varvara MD, S Koppolu MBBS, Z Yaseen MD, I Galynker MD PhD
Cranial Electrical Stimulation (CES) technology has been used widely for treatment of depression, anxiety and insomnia, but to date, there have been no studies examining the efficacy of this technology to treat bipolar II depression. Our goal in this study was to evaluate the use of CES for treatment of the symptoms of depression in bipolar II disorder. We examined changes in levels of depression and quality of life during the four week treatment period.
The sixteen participants were 50% female, with a mean age of 47.69 (15.88), and an average level of education of 16.81 (2.401) years.(p=.012), but no significant change from baseline to week two. In the placebo group, there was a significant change from baseline to 2 weeks on HAM-D scores, (p=.015), and during the open label treatment phase from 2 weeks to 4 weeks, (p=.022). In the active group, there was a significant decrease in severity scores using CGI-S from baseline to second week, and baseline to 4th week, (p=.017), while there is no significant difference in means for the placebo group.
Our preliminary results indicate that the active group had significantly higher reduction in depression levels compared to the placebo group. During the double-blind randomized and controlled trial of the first 2 weeks, there was a significant decrease in BDI scores for only the active group. However, the data displays improvement effects for both groups on the Hamilton Depression Rating Scale, which may be due to the difference in brain regions associated with HAM-D and BDI.